JP2009534323A - 非経口栄養のための小児用アミノ酸溶液 - Google Patents
非経口栄養のための小児用アミノ酸溶液 Download PDFInfo
- Publication number
- JP2009534323A JP2009534323A JP2009505732A JP2009505732A JP2009534323A JP 2009534323 A JP2009534323 A JP 2009534323A JP 2009505732 A JP2009505732 A JP 2009505732A JP 2009505732 A JP2009505732 A JP 2009505732A JP 2009534323 A JP2009534323 A JP 2009534323A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid solution
- solution according
- per
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 120
- 235000016236 parenteral nutrition Nutrition 0.000 title claims abstract description 30
- 235000001014 amino acid Nutrition 0.000 claims abstract description 107
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 31
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 27
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 26
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 25
- 235000018417 cysteine Nutrition 0.000 claims abstract description 16
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 14
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 14
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003080 taurine Drugs 0.000 claims abstract description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 9
- 229930182817 methionine Natural products 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 17
- 235000018102 proteins Nutrition 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 11
- 108010016626 Dipeptides Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229960002648 alanylglutamine Drugs 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 5
- 235000013619 trace mineral Nutrition 0.000 claims description 5
- 239000011573 trace mineral Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 108010044940 alanylglutamine Proteins 0.000 claims description 2
- 108010087823 glycyltyrosine Proteins 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000020455 intestinal malformation Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- ALZVPLKYDKJKQU-XVKPBYJWSA-N Ala-Tyr Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ALZVPLKYDKJKQU-XVKPBYJWSA-N 0.000 claims 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 claims 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 claims 1
- 108010070783 alanyltyrosine Proteins 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims 1
- 108010010147 glycylglutamine Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 8
- 229940024606 amino acid Drugs 0.000 description 74
- 239000000243 solution Substances 0.000 description 37
- 229960004441 tyrosine Drugs 0.000 description 20
- 229960002433 cysteine Drugs 0.000 description 13
- 230000002028 premature Effects 0.000 description 13
- 239000002243 precursor Substances 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 206010036590 Premature baby Diseases 0.000 description 6
- -1 tyrosine amino acids Chemical class 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017877 Gastrointestinal fistula Diseases 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 108010058198 sulfoalanine decarboxylase Proteins 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006018293A DE102006018293A1 (de) | 2006-04-20 | 2006-04-20 | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| PCT/EP2007/001878 WO2007121807A1 (de) | 2006-04-20 | 2007-03-05 | Paediatrische aminosäurelösung zur parenteralen ernährung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534323A true JP2009534323A (ja) | 2009-09-24 |
| JP2009534323A5 JP2009534323A5 (enExample) | 2010-04-08 |
Family
ID=38006821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505732A Pending JP2009534323A (ja) | 2006-04-20 | 2007-03-05 | 非経口栄養のための小児用アミノ酸溶液 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8377876B2 (enExample) |
| EP (1) | EP2007348B1 (enExample) |
| JP (1) | JP2009534323A (enExample) |
| KR (1) | KR20090010050A (enExample) |
| CN (2) | CN101420933A (enExample) |
| AR (1) | AR060555A1 (enExample) |
| AU (1) | AU2007241469B2 (enExample) |
| BR (1) | BRPI0710298A2 (enExample) |
| CA (1) | CA2647087A1 (enExample) |
| DE (1) | DE102006018293A1 (enExample) |
| EA (1) | EA015709B1 (enExample) |
| MX (1) | MX2008013540A (enExample) |
| TW (1) | TWI429405B (enExample) |
| WO (1) | WO2007121807A1 (enExample) |
| ZA (1) | ZA200807860B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011121889A (ja) * | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2011144116A (ja) * | 2010-01-12 | 2011-07-28 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用添加剤 |
| JP2020522491A (ja) * | 2017-05-31 | 2020-07-30 | ナポ ファーマシューティカルズ インク．Ｎａｐｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065698A (zh) | 2008-06-19 | 2011-05-18 | 荷兰联合利华有限公司 | 具有铁和锌的含脂肪食用乳液 |
| AU2009268742C1 (en) | 2008-07-07 | 2013-11-28 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| CA2786375A1 (en) * | 2010-01-04 | 2011-07-07 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| US20110208153A1 (en) * | 2010-02-24 | 2011-08-25 | John Alvey | Formulations and methods for nutrient delivery |
| JP6000253B2 (ja) | 2010-09-24 | 2016-09-28 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 胃腸機能を改善するための材料および方法 |
| EP2489408A1 (de) * | 2011-01-13 | 2012-08-22 | Michael Tchirikov | Aminosäurezusammensetzung und deren Verwendung zur Behandlung von fetaler Wachstumsrestriktion (IUGR) und zur parenteralen Ernährung von extrem Frühgeborenen |
| CN104039174B (zh) * | 2012-01-09 | 2016-11-16 | N·V·努特里奇亚 | 用于早产婴儿的富含谷氨酰胺的营养组合物 |
| MX368543B (es) * | 2012-02-08 | 2019-10-07 | Univ Florida | Composiciones para tratar diarrea inducida por rotavirus. |
| BR112015016465B1 (pt) * | 2013-01-09 | 2020-11-10 | N.V. Nutricia | uso de glutamina ou de uma composição; método não-medicinal para melhora posterior da função cognitiva em um bebê muito prematuro nascido pequeno para a idade gestacional; e método não-medicinal para melhora posterior do q.i em um bebê muito prematuro nascido pequeno para a idade gestacional |
| WO2014164736A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| CN103404934B (zh) * | 2013-08-24 | 2015-07-01 | 江苏阜丰生物科技有限公司 | 一种含谷氨酰胺的解酒固体饮料及其制备方法 |
| WO2015178762A1 (en) * | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Enteral formulations for preterm infants comprising optimised phenylalanine intake levels |
| WO2015178761A1 (en) | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Formulas comprising optimised amino acid profiles |
| CN107898808B (zh) * | 2017-10-31 | 2021-04-27 | 华仁药业股份有限公司 | 小儿用静脉营养制剂 |
| RU2699222C1 (ru) * | 2019-04-29 | 2019-09-04 | Алексей Владимирович Воронов | Солевой электролитный раствор для проведения энтеральных инфузий |
| EP4125436A4 (en) * | 2020-04-01 | 2024-05-15 | The E. Wolfson Medical Center | ULCEROUS COLITIS DIET, RELATED FORMULAS, PRODUCTS AND METHODS |
| US20220378077A1 (en) * | 2021-05-25 | 2022-12-01 | Baxter International Inc. | Ready-To-Use Parenteral Nutrition Formulation |
| IT202200015885A1 (it) * | 2022-07-27 | 2024-01-27 | St G Gaslini | Sacca standardizzata per alimentazione di nati pretermine e dispositivo di alimentazione di nati pretermine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06227974A (ja) * | 1993-01-29 | 1994-08-16 | Kyowa Hakko Kogyo Co Ltd | 栄養組成物 |
| JPH0710770A (ja) * | 1990-03-14 | 1995-01-13 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3206784C2 (de) * | 1982-02-25 | 1985-05-09 | Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen | Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation |
| FR2556594B1 (fr) * | 1983-12-20 | 1988-09-09 | Synthelabo | Solutions d'acides amines |
| US5684045A (en) * | 1985-09-12 | 1997-11-04 | Brigham And Women's Hospital | Method of treating pancreatic atrophy |
| US5206220A (en) * | 1990-04-23 | 1993-04-27 | Research Corporation Technologies, Inc. | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition |
| JPH05507472A (ja) * | 1990-04-23 | 1993-10-28 | リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド | 経静脈栄養法のためのチロシン、システイン、グルタミンの可溶性で安定な供給源 |
| SE9003844L (sv) * | 1990-12-03 | 1992-06-04 | Kabi Pharmacia Ab | Naeringstillsats |
| US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
| FR2711529B1 (fr) * | 1993-10-28 | 1996-07-05 | Clintec Nutrition Cy | Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme. |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| US5561111A (en) * | 1994-12-23 | 1996-10-01 | The University Of Virginia Patent Foundation | Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| ID27818A (id) * | 1998-03-31 | 2001-04-26 | Nestle Sa | Metode untuk menyediakan glutamin |
| US7148199B2 (en) * | 2003-09-26 | 2006-12-12 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
-
2006
- 2006-04-20 DE DE102006018293A patent/DE102006018293A1/de not_active Ceased
-
2007
- 2007-03-05 WO PCT/EP2007/001878 patent/WO2007121807A1/de not_active Ceased
- 2007-03-05 AU AU2007241469A patent/AU2007241469B2/en not_active Ceased
- 2007-03-05 CA CA002647087A patent/CA2647087A1/en not_active Abandoned
- 2007-03-05 JP JP2009505732A patent/JP2009534323A/ja active Pending
- 2007-03-05 CN CNA2007800136921A patent/CN101420933A/zh active Pending
- 2007-03-05 CN CN201410705858.8A patent/CN104524542A/zh active Pending
- 2007-03-05 US US12/226,358 patent/US8377876B2/en not_active Expired - Fee Related
- 2007-03-05 MX MX2008013540A patent/MX2008013540A/es active IP Right Grant
- 2007-03-05 BR BRPI0710298-4A patent/BRPI0710298A2/pt not_active IP Right Cessation
- 2007-03-05 EA EA200870451A patent/EA015709B1/ru not_active IP Right Cessation
- 2007-03-05 KR KR1020087027628A patent/KR20090010050A/ko not_active Withdrawn
- 2007-03-05 EP EP07711788.5A patent/EP2007348B1/de not_active Not-in-force
- 2007-03-08 TW TW096108010A patent/TWI429405B/zh not_active IP Right Cessation
- 2007-04-20 AR ARP070101703A patent/AR060555A1/es unknown
-
2008
- 2008-09-12 ZA ZA200807860A patent/ZA200807860B/xx unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710770A (ja) * | 1990-03-14 | 1995-01-13 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| JPH06227974A (ja) * | 1993-01-29 | 1994-08-16 | Kyowa Hakko Kogyo Co Ltd | 栄養組成物 |
Non-Patent Citations (7)
| Title |
|---|
| JPN5009004033; ＬＡＣＥＹ ＪＭ: ＪＰＥＮ Ｖ２０ Ｎ１, 199601, Ｐ７４-８０ * |
| JPN6012047941; 小児科診療 ４８（１２）, 1985, ２３４３-２３４７ * |
| JPN6012047942; 日本外科代謝栄養学会 ２６（４）, 1992, ３４８-３５５ * |
| JPN6013012027; 医学のあゆみ １３１（１０）, 1984, ６５３-６５５ * |
| JPN6013012028; 医薬ジャーナル ２６（８）, 1990, １７１２-１７１３ * |
| JPN6013012029; ＪＪＰＥＮ 輸液・栄養ジャーナル １８（５）, 1996, ３８７-３９２ * |
| JPN6013012030; 周産期医学 ３１（５）, 2001, ７０６-７１０ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011121889A (ja) * | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2011144116A (ja) * | 2010-01-12 | 2011-07-28 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用添加剤 |
| JP2020522491A (ja) * | 2017-05-31 | 2020-07-30 | ナポ ファーマシューティカルズ インク．Ｎａｐｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物 |
| JP7328153B2 (ja) | 2017-05-31 | 2023-08-16 | ナポ ファーマシューティカルズ インク． | 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物 |
| US11779564B2 (en) | 2017-05-31 | 2023-10-10 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| EA015709B1 (ru) | 2011-10-31 |
| BRPI0710298A2 (pt) | 2011-08-09 |
| US20090203626A1 (en) | 2009-08-13 |
| EA200870451A1 (ru) | 2009-04-28 |
| AR060555A1 (es) | 2008-06-25 |
| WO2007121807A1 (de) | 2007-11-01 |
| US8377876B2 (en) | 2013-02-19 |
| MX2008013540A (es) | 2008-10-31 |
| CN104524542A (zh) | 2015-04-22 |
| CN101420933A (zh) | 2009-04-29 |
| ZA200807860B (en) | 2009-08-26 |
| EP2007348B1 (de) | 2014-12-10 |
| KR20090010050A (ko) | 2009-01-28 |
| TWI429405B (zh) | 2014-03-11 |
| AU2007241469A1 (en) | 2007-11-01 |
| EP2007348A1 (de) | 2008-12-31 |
| CA2647087A1 (en) | 2007-11-01 |
| AU2007241469B2 (en) | 2012-09-20 |
| TW200740380A (en) | 2007-11-01 |
| DE102006018293A1 (de) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534323A (ja) | 非経口栄養のための小児用アミノ酸溶液 | |
| AU679020B2 (en) | Medical foods for the nutritional support of infant/toddler metabolic diseases | |
| AU669252B2 (en) | Medical foods for the nutritional support of child/adult metabolic diseases | |
| Kenji Imura et al. | Amino acid metabolism in pediatric patients | |
| AU2003266400C1 (en) | Leucine-enriched nutritional compositions | |
| ES2586402T3 (es) | Composiciones de hidroximetilbutirato y usos de las mismas | |
| EP0705542B1 (en) | Adolescent dietary composition | |
| CA2133783C (en) | Enteral nutritional composition | |
| ES2221676T3 (es) | Suplemento nutricional para pacientes pediatricos. | |
| JP5315996B2 (ja) | 総合経腸栄養組成物 | |
| ES2341538T3 (es) | Composiciones nutricionales o farmaceuticas para aumentar la respuesta a la creatina de organismos. | |
| RU2003117716A (ru) | Энтерально вводимая добавка для парентерального питания или частичного энтерального/орального питания в случае критических больных, хронических больных и больных с недостаточным питанием | |
| BRPI0718384A2 (pt) | Alimentação a longo prazo para pacientes com câncer | |
| ZA200403687B (en) | Use of cystathionine. | |
| Serrano et al. | Nutrition support of infants with short bowel syndrome | |
| JPH0328403B2 (enExample) | ||
| JPWO1988008259A1 (ja) | 栄養乳液製剤 | |
| HK1005768B (en) | Adolescent dietary composition | |
| ZA200501922B (en) | Leucine-enriched nutritional compositions. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120911 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121207 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130212 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130319 |